Cargando…
Clinical outcome of patients with pancreatic metastases from renal cell cancer
BACKGROUND: Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332740/ https://www.ncbi.nlm.nih.gov/pubmed/25872621 http://dx.doi.org/10.1186/s12885-015-1050-2 |
_version_ | 1782357951983386624 |
---|---|
author | Yuasa, Takeshi Inoshita, Naoko Saiura, Akio Yamamoto, Shinya Urakami, Shinji Masuda, Hitoshi Fujii, Yasuhisa Fukui, Iwao Ishikawa, Yuichi Yonese, Junji |
author_facet | Yuasa, Takeshi Inoshita, Naoko Saiura, Akio Yamamoto, Shinya Urakami, Shinji Masuda, Hitoshi Fujii, Yasuhisa Fukui, Iwao Ishikawa, Yuichi Yonese, Junji |
author_sort | Yuasa, Takeshi |
collection | PubMed |
description | BACKGROUND: Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC. METHODS: Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed. RESULTS: The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8–15.5 years) and 3.8 years (IQR, 2.1–5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2–12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for these surgeries was 3.5 years (IQR, 1.9–5.2 years), the estimated median recurrence-free survival was 1.8 years. For the patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the median follow-up period was 4.1 years (IQR, 3.0–4.4 years), no disease progression was observed. CONCLUSIONS: The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good outcomes. |
format | Online Article Text |
id | pubmed-4332740 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43327402015-02-20 Clinical outcome of patients with pancreatic metastases from renal cell cancer Yuasa, Takeshi Inoshita, Naoko Saiura, Akio Yamamoto, Shinya Urakami, Shinji Masuda, Hitoshi Fujii, Yasuhisa Fukui, Iwao Ishikawa, Yuichi Yonese, Junji BMC Cancer Research Article BACKGROUND: Renal cell cancer (RCC) is one of the most frequent primary sites for metastatic pancreatic tumors although metastatic tumors are rare among pancreatic malignant tumors. The purpose of this study is to disclose the characterization and treatment outcomes of pancreatic metastases from RCC. METHODS: Of 262 patients with metastatic RCC treated at our hospital between 1999 and 2013, the data of 20 (7.6%) who simultaneously developed or subsequently acquired pancreatic metastases were retrospectively reviewed and statistically analyzed. RESULTS: The median follow-up period from RCC diagnosis and pancreatic metastases was 13.4 years (inter-quartile range: IQR, 7.8–15.5 years) and 3.8 years (IQR, 2.1–5.5 years), respectively. Median duration from diagnosis of RCC to pancreatic metastasis was 7.8 years (IQR, 4.2–12.7 years). During this observation period, the estimated median overall survival (OS) time from the diagnosis of RCC to death or from pancreatic metastasis to death was not reached. The probability of patients surviving after pancreatic metastasis at 1, 3, and 5 years was 100, 87.7, and 78.9%, respectively. The estimated OS period from the diagnosis of metastases to death of the patients with pancreatic metastasis was significantly longer than that of the patients with non-pancreatic metastasis (median OS 2.7 years) (P < 0.0001). Surgical management for pancreatic metastasis was performed in 15 patients (75%). When the median follow-up period for these surgeries was 3.5 years (IQR, 1.9–5.2 years), the estimated median recurrence-free survival was 1.8 years. For the patients with multiple metastatic sites, molecularly targeted therapies were given to six (30%) patients. When the median follow-up period was 4.1 years (IQR, 3.0–4.4 years), no disease progression was observed. CONCLUSIONS: The pancreas is frequently the only metastatic site and metastasis typically occurs a long time after nephrectomy. The OS period of these patients is long and both surgical and medical treatment resulted in good outcomes. BioMed Central 2015-02-12 /pmc/articles/PMC4332740/ /pubmed/25872621 http://dx.doi.org/10.1186/s12885-015-1050-2 Text en © Yuasa et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Yuasa, Takeshi Inoshita, Naoko Saiura, Akio Yamamoto, Shinya Urakami, Shinji Masuda, Hitoshi Fujii, Yasuhisa Fukui, Iwao Ishikawa, Yuichi Yonese, Junji Clinical outcome of patients with pancreatic metastases from renal cell cancer |
title | Clinical outcome of patients with pancreatic metastases from renal cell cancer |
title_full | Clinical outcome of patients with pancreatic metastases from renal cell cancer |
title_fullStr | Clinical outcome of patients with pancreatic metastases from renal cell cancer |
title_full_unstemmed | Clinical outcome of patients with pancreatic metastases from renal cell cancer |
title_short | Clinical outcome of patients with pancreatic metastases from renal cell cancer |
title_sort | clinical outcome of patients with pancreatic metastases from renal cell cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4332740/ https://www.ncbi.nlm.nih.gov/pubmed/25872621 http://dx.doi.org/10.1186/s12885-015-1050-2 |
work_keys_str_mv | AT yuasatakeshi clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT inoshitanaoko clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT saiuraakio clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT yamamotoshinya clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT urakamishinji clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT masudahitoshi clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT fujiiyasuhisa clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT fukuiiwao clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT ishikawayuichi clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer AT yonesejunji clinicaloutcomeofpatientswithpancreaticmetastasesfromrenalcellcancer |